Jinghua Pharmaceutical Group Co 002349.SZ · CNY

Its shares trade on Shenzhen under the ticker 002349.SZ. It has been listed since 3 February 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.46bn and net income of CN¥219.3m. At that date it held total assets of CN¥3.57bn and shareholders' equity of CN¥2.75bn.

Jinghua Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing. The company is headquartered in Nantong, Jiangsu. The company went IPO on 2010-02-03. The firm is also engaged in the provision of traditional Chinese medicinal materials and Chinese herbal pieces, among others. The firm primarily provides tablets, capsules, pills, granules, injections, powder, syrup, healthcare products, beverages and chemical intermediates, among others. The firm offers Chinese patent medicines, such as Wangshi Baochiwan pills and Jidesheng tablets. Its bulk drugs include phenobarbitone and fluorouracil. The firm distributes its products in domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Hongyu YinChairman of the Board
• Mr. Yuxiang WuFinance Director, Executive Deputy General Manager, Director, since 2011CN¥775,500
• Mr. Yunzhong ZhouGeneral Manager, DirectorCN¥932,200
• Mr. Jian ChengDeputy General ManagerCN¥697,700
• Mr. Qianyong ZhuDeputy General ManagerCN¥745,900
• Mr. Jianfeng WangSecretary of the Board, since 2021CN¥542,200
• Mr. Jianqiao ZhangDirector
• Mr. Qiaogen FengIndependent DirectorCN¥112,500
• Ms. Ling MaIndependent DirectorCN¥37,500
• Mr. Xu WangIndependent DirectorCN¥37,500

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.